Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

NCT04760730 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: AZD1222
BIOLOGICAL: rAd26-S

Sponsor

R-Pharm

Collaborators

[object Object]